Bachem Targets Billion-Franc Revenue Milestone Under New Leadership

Bachem targets first billion-franc year, but growth hinges on new production facilities. Stock is volatile but technically oversold as key shareholder dates approach.

The Swiss pharmaceutical firm Bachem is on course to achieve a significant financial landmark. With Anne-Kathrin Stoller now at the helm as CEO, the company has set its sights on surpassing annual revenues of one billion Swiss francs for the first time. Realizing this ambitious strategy is heavily dependent on bringing new large-scale production facilities online, a process that has so far been met with cautious skepticism by the market, reflected in the stock's recent performance.

Capacity Expansion Central to Growth Strategy

A core element of Bachem's growth plan, which targets a 35% to 45% increase in local currencies, is centered on its Bubendorf site. The phased commissioning of "Building K" there is designed to provide the essential capacity needed to handle large-volume orders for peptide-based active pharmaceutical ingredients. This technological push represents the focal point of the company's current phase, though it demands substantial capital expenditure.

Management has budgeted for investment spending exceeding 400 million CHF for the current year alone. These funds are allocated not only to the Swiss expansion but also to enhancing the global production network, including facilities in the United States. Market analysts are closely monitoring the impact on profitability, questioning whether the EBITDA margin can be maintained steadily in the low 30-percent range despite these significant ramp-up costs.

Share Price Volatility and Technical Indicators

On the London Stock Exchange, Bachem shares traded weaker, with the price at 63.65 GBP. The session's decline of 4.36% continues a recent pattern of volatility. However, technical indicators suggest a potential shift: the Relative Strength Index (RSI) reading of 25.4 signals a deeply oversold condition, which may attract technically-driven investors anticipating a near-term price floor. The current share price sits approximately 14.7% below its 52-week high.

Key upcoming events for shareholders include:
* 29 April 2026: The Ordinary General Meeting, where a vote will be held on increasing the dividend to 0.90 CHF.
* 30 July 2026: The publication of the detailed financial report for the second quarter.

These events will provide critical evidence on whether the operational momentum in the first half of the year is sufficient to support the full-year ambitions. The Q2 report in late July, in particular, is likely to determine if the stock can break out of its recent sideways trading pattern and begin a renewed ascent toward its annual highs.